Advertisement
Canada markets closed
  • S&P/TSX

    21,947.41
    +124.21 (+0.57%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +449.98 (+1.18%)
     
  • CAD/USD

    0.7307
    -0.0007 (-0.09%)
     
  • CRUDE OIL

    78.40
    +0.29 (+0.37%)
     
  • Bitcoin CAD

    87,264.07
    +15.88 (+0.02%)
     
  • CMC Crypto 200

    1,327.95
    +50.97 (+3.99%)
     
  • GOLD FUTURES

    2,311.60
    +3.00 (+0.13%)
     
  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • NASDAQ futures

    18,032.75
    +32.00 (+0.18%)
     
  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     
  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

US FDA approves Otsuka's blood pressure treatment device for use

Nov 8 (Reuters) - The U.S. Food and Drug Administration (FDA) approved the use of a device made by an Otsuka Holdings unit in a type of surgery to treat high blood pressure, the company said on Wednesday.

The approval for Paradise Ultrasound Renal Denervation comes after an FDA panel backed its use.

The device is made by Japanese company Otsuka's unit ReCor and is indicated for use in patients whose hypertension, or high blood pressure, cannot be controlled with drugs.

ReCor's device, which is a balloon-like structure inside a catheter, is inserted through a small cut into the kidney's arteries and sends ultrasound energy to burn nerves that are believed to control blood pressure.

The surgery has been previously approved in Europe and other parts of the world. (Reporting by Gursimran Kaur in Bengaluru; Editing by Subhranshu Sahu)